Dexcom G7 15 Day is the longest‑lasting and most accurate 1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days 5. BURNABY, British ...

DexCom DXCM recently announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System has received ...

The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility.

Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes.

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

New data from Dexcom has demonstrated the benefit of its G7 continuous glucose monitor (CGM) in type 2 diabetes (TD2) patients not receiving insulin, suggesting a new standard of care (SoC) could be ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Ontario government for its recent decision to include the Dexcom G7 ...